Recent Company News

• 09:35 PM ET Apr 07, 2026
  

  StreetAccount Sector Summary - China Healthcare March Recap

• 02:45 AM ET Apr 03, 2026
  

  Japan approves Novartis's Zolgensma (CHF 123.20, 0.00)

• 03:40 PM ET Apr 02, 2026
  

  White House announces tariffs on patented pharmaceuticals

• 02:00 PM ET Mar 30, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 23-Mar

• 10:38 AM ET Mar 30, 2026
  

  StreetAccount M&A Summary: Week of 23-Mar

• 05:33 AM ET Mar 29, 2026
  

  Novartis presents, publishes final two-year results from APPLAUSE-IgAN study of Fabhalta (CHF 119.14, 0.00)

• 08:15 AM ET Mar 27, 2026
  

  EU's CHMP adopted a positive opinion recommending change to terms of marketing authorisation for Tafinlar (CHF 119.34, -0.18)

• 08:07 AM ET Mar 27, 2026
  

  Follow-up: EU's CHMP adopted a positive opinion recommending change to terms of marketing authorisation for Mekinist (CHF 119.38, -0.14)

• 08:02 AM ET Mar 27, 2026
  

  EU's CHMP adopted a positive opinion recommending change to terms of marketing authorisation for Mekinist (CHF 119.26, -0.26)

• 07:47 AM ET Mar 27, 2026
  

  Industrials, tech, basic resources and energy the big laggards; chemicals, healthcare, insurance the outperformers;